What Microdosing Is — and Isn't
Microdosing psilocybin means taking a sub-perceptual dose — typically 50–300mg of dried psilocybin mushroom — on a regular schedule. "Sub-perceptual" is the key term: the goal is to take enough to produce neurochemical effects without producing any noticeable psychedelic experience. If you feel high, see anything unusual, or feel impaired, the dose is too high.
The practice moved from underground use to mainstream research subject between 2018 and 2023. The 2021 Scientific Reports study — the largest observational study of microdosing ever conducted, with over 4,000 participants — found that microdosers reported significant improvements in depression, anxiety, focus, and emotional regulation compared to non-microdosing controls. Subsequent controlled trials have begun to confirm these findings.
The Protocols
Three schedules dominate the research literature and practitioner community:
The Fadiman Protocol (developed by psychedelic researcher James Fadiman): dose on day 1, rest on days 2 and 3, repeat. This is the most studied protocol and the one used in most observational research. The two rest days prevent receptor tolerance from developing.
The 4-on, 3-off Protocol: dose Monday through Thursday, rest Friday through Sunday. This aligns with a standard work week and is particularly popular among people using microdosing for professional performance. The 3 consecutive rest days provide a longer tolerance reset.
The Stamets Protocol (developed by mycologist Paul Stamets): 4 days on, 3 days off, combining psilocybin with lion's mane mushroom and niacin. The addition of lion's mane is proposed to enhance neuroplasticity effects; the niacin is proposed to improve absorption and distribution. This protocol has not been formally studied but is widely used.
Dosing
The standard microdose range is 50–300mg of dried psilocybin mushroom (equivalent to approximately 0.5–3mg of pure psilocybin). Most people find their optimal dose in the 100–150mg range.
The principle is to start low and adjust. Begin at 50–100mg for the first two weeks. If you notice no effects (positive or negative), increase by 25–50mg. If you notice unwanted effects — anxiety, overstimulation, emotional intensity — reduce the dose. The goal is a dose that produces subtle improvements in focus, mood, and cognitive flexibility without any perceptible alteration of consciousness.
Capsule-based products (like Shrooomz Secret Capsules at 150mg) provide consistent, pre-measured doses that eliminate the variability of self-measured powder.
What to Expect
The effects of microdosing are typically described as: slightly improved mood, increased motivation, better focus and cognitive flexibility, reduced anxiety, and greater emotional resilience. These effects are subtle — they are noticed in retrospect ("I handled that difficult conversation better than I usually would") rather than felt acutely.
The 2021 Scientific Reports study found the most commonly reported benefits were: improved mood (reported by 26.6% of participants), focus (14.8%), creativity (12.9%), and reduced anxiety (12.2%). The most commonly reported challenges were: physiological discomfort (18.0%), increased anxiety (6.7%), and difficulty with timing/scheduling (6.4%).
Who Should Not Microdose
Microdosing is contraindicated for people with a personal or family history of psychosis or schizophrenia — psilocybin can exacerbate psychotic symptoms even at sub-threshold doses. It is also not recommended during pregnancy or breastfeeding, or in combination with lithium (which increases seizure risk with psilocybin). People taking SSRIs may find microdosing less effective due to serotonin receptor downregulation from the SSRI, but this is a pharmacological interaction rather than a safety concern.
The Research Gap
Most microdosing research is observational — participants self-select and self-report. The controlled trials that have been conducted (including a 2022 Imperial College London double-blind trial) have found smaller effect sizes than observational studies, suggesting some expectancy effects. The honest position is that microdosing has a strong signal of benefit in observational data, a smaller but real signal in controlled data, and an excellent safety profile. It is a reasonable intervention for people who want to try it, with realistic expectations about the magnitude of effect.